Leucid Bio

Leucid is a biotechnology company focused on developing advanced CAR T cell therapies to treat refractory cancers. The company operates in the biopharmaceutical market, targeting healthcare providers and patients who require innovative cancer treatments. Leucid's core product is its proprietary parallel CAR T (pCAR T) therapies, which are designed to be more effective and long-lasting compared to previous CAR T generations. These therapies involve genetically altering immune cells to hunt down and destroy cancer cells, offering a promising solution for patients with limited treatment options.

Leucid's business model revolves around the research, development, and commercialization of its pCAR T therapies. The company generates revenue through partnerships with healthcare institutions, licensing agreements, and potentially through direct sales of its therapies once they receive regulatory approval. Leucid has also developed a more rapid and scalable manufacturing process, which relies on a simple blood draw, making the production of its therapies more efficient and accessible.

Keywords: CAR T therapy, refractory cancers, pCAR T, T cell potency, durable response, biotechnology, biopharmaceutical, cancer treatment, scalable manufacturing, immune cells.